Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,474 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,543 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07643831 | Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer | available | — | — | Genentech, Inc.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06834074 | Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors(NVL-655-EAP) | available | — | — | Nuvalent Inc.INDUSTRY | 12 | Sep 21, 2026 |
| clinicaltrials |
| NCT07346105 | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies | available | — | — | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07825701 | Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT Mutations | available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Sep 17, 2026 | clinicaltrials |
| NCT05494411 | Named Patient Program for Mitomycin for Pyelocalyceal Solution | available | — | — | UroGen Pharma Ltd.INDUSTRY | 0 | Sep 15, 2026 | clinicaltrials |
| NCT06443944 | An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG | available | — | — | CG Oncology, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07535359 | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer | available | — | — | Daiichi SankyoINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06797362 | Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors | available | — | — | Nuvalent Inc.INDUSTRY | 10 | Aug 25, 2026 | clinicaltrials |
| NCT06617572 | Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel | available | — | — | USWM CT, LLCINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03015844 | A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma | available | — | — | Northwell HealthOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07748299 | NuvOx Expanded Access | available | — | — | NuvOx LLCINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT01370330 | 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol | available | — | — | Kieuhoa VoOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07614048 | Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS | available | — | — | Providence Health & ServicesOTHER | 0 | Jul 23, 2026 | clinicaltrials |
| NCT06948955 | Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors | available | — | — | Cogent Biosciences, Inc.INDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03145545 | Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC | available | — | — | Children's Hospital of PhiladelphiaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06761976 | Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation | available | — | — | BayerINDUSTRY | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07675057 | Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors | available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Jun 30, 2026 | clinicaltrials |
| NCT04809233 | Expanded Access to Tipifarnib(Kuraoncology) | available | — | — | Kura Oncology, Inc.INDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT05738538 | Expanded Access to Ziftomenib | available | — | — | Kura Oncology, Inc.INDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT05776160 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT07601399 | An EAP Treatment Protocol of Zipalertinib | available | — | — | Taiho Oncology, Inc.INDUSTRY | 0 | Jun 11, 2026 | clinicaltrials |
| NCT06404034 | Expanded Access to Gallium Maltolate (GaM) | available | — | — | Imaging Biometrics, LLCINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07612930 | Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy | available | — | — | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.INDUSTRY | 0 | May 29, 2026 | clinicaltrials |
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT06810141 | ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer | available | — | — | ImmunityBio, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT04571229 | Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma | available | — | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05028166 | Individual Patient Compassionate Use of Mirdametinib | available | — | — | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 0 | May 8, 2026 | clinicaltrials |
| NCT05041036 | Individual Patient Compassionate Use of Nirogacestat | available | — | — | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 0 | May 8, 2026 | clinicaltrials |
| NCT01916148 | 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia | available | — | — | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05511714 | Expanded Access [11C] Methionine PET Imaging | available | — | — | St. Jude Children's Research HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05593185 | Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS | available | — | — | Sellas Life Sciences GroupINDUSTRY | 0 | Apr 24, 2026 | clinicaltrials |
| NCT03601442 | Managed Access Programs for CTL019, Tisagenlecleucel | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 23, 2026 | clinicaltrials |
| NCT04085653 | Managed Access Programs for BYL719, Alpelisib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 14, 2026 | clinicaltrials |
| NCT01163383 | 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol | available | — | — | John MarisOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05038631 | Managed Access Programs for LEE011, Ribociclib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05776134 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07502716 | Compassionate Use of Ubamatamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT07497984 | ITM11 Expanded Access Program | available | — | — | ITM Solucin GmbHINDUSTRY | 0 | Mar 27, 2026 | clinicaltrials |
| NCT04091295 | BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast | available | — | — | Aveni FoundationOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT06799221 | Expanded Access Program for OOS Obe-cel | available | — | — | Autolus LimitedINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06836648 | Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer | available | — | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03581240 | An Intermediate Expanded Use Trial of DFMO | available | — | — | Giselle ShollerOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05346835 | Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma | available | — | — | Janssen Scientific Affairs, LLCINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT07310277 | Expanded Access to ABBV-706 | available | — | — | AbbVieINDUSTRY | 0 | Jan 29, 2026 | clinicaltrials |
| NCT05619367 | A Compassionate Use (CU) Program of Odronextamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Dec 23, 2025 | clinicaltrials |
| NCT04771078 | Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release | available | — | — | CelgeneINDUSTRY | 0 | Dec 12, 2025 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials